CAJ | 학술논문

目的探讨护肝宁片对大鼠非酒精性脂肪性肝炎的治疗作用及机制.方法雄性SD大鼠39只,正常喂养1周后按体质量层次随机分为正常对照组(n=9)和实验组(n=30),正常对照组予标准饮食,实验组予高脂饮食.11周末验证造模成功后,将余下25只实验组大鼠再分为:高脂组、饮食治疗组,及护肝宁高剂量组、中剂量组、低剂量组.分别给予高剂量、中剂量、低剂量护肝宁片灌胃及标准饮食.16周末处死大鼠,检测肝指数、体脂比、血清ALT、AST、TC、TG、LDL-C、血糖、超氧化物歧化酶(SOD)、丙二醛,并行肝组织病理检查及肝匀浆TC,TG,LDL-C和丙二醛测定.结果护肝宁中剂量组、护肝宁低剂量组体脂比[分别为(3.08±0.49)%与(3.07±0.82)%]较饮食治疗组及高脂组降低(P<0.05);护肝宁高剂量组血清AST水平、TC水平、血糖水平及肝匀浆TC水平[分别为(119.8±14.7)U/L、(1.59±0.38)mmol/L、(5.44±0.44)mmol/L及(0.34±0.07)mmol/L]明显低于饮食治疗组,护肝宁高剂量组血清SOD水平[(47.38±5.72)%]明显高于饮食治疗组(P<0.05);护肝宁高剂量组较饮食治疗组及高脂组肝组织的脂肪变程度、炎症程度和纤维化程度均明显减轻(JP<0.05).结论护肝宁片可有效治疗大鼠非酒精性脂肪性肝炎.
목적 탐토호간저편대대서비주정성지방성간염적치료작용급궤제.방법 웅성SD대서39지,정상위양1주후안체질량층차수궤분위정상대조조(n=9)화실험조(n=30),정상대조조여표준음식,실험조여고지음식.11주말험증조모성공후,장여하25지실험조대서재분위:고지조、음식치료조,급호간저고제량조、중제량조、저제량조.분별급여고제량、중제량、저제량호간저편관위급표준음식.16주말처사대서,검측간지수、체지비、혈청ALT、AST、TC、TG、LDL-C、혈당、초양화물기화매(SOD)、병이철,병행간조직병리검사급간균장TC,TG,LDL-C화병이철측정.결과 호간저중제량조、호간저저제량조체지비[분별위(3.08±0.49)%여(3.07±0.82)%]교음식치료조급고지조강저(P<0.05);호간저고제량조혈청AST수평、TC수평、혈당수평급간균장TC수평[분별위(119.8±14.7)U/L、(1.59±0.38)mmol/L、(5.44±0.44)mmol/L급(0.34±0.07)mmol/L]명현저우음식치료조,호간저고제량조혈청SOD수평[(47.38±5.72)%]명현고우음식치료조(P<0.05);호간저고제량조교음식치료조급고지조간조직적지방변정도、염증정도화섬유화정도균명현감경(JP<0.05).결론 호간저편가유효치료대서비주정성지방성간염.
Objective To investigate the protective effect and mechanism of Huganning tablet on rat model of nonalcoholic steatohepatitis( NASH). Methods After one week of a standard diet 39 male SD rats were random-ly divided into the normal control group(n =9) and the experimental group(n =30). The normal control group rats were fed with a standard diet, while those of the experimental group had a high-fat diet. After 10 weeks 9 rats were sacrificed to verify whether the model was established successfully. Then the experimental group was randomly sub-divided into five groups :Group Z(n =5) with a high-fat diet and gastric with saline, GroupY(n=5) with a stand-ard diet and gastric with saline, GroupA(n=5), Group B(n=5) and Group C(n =5) with a standard diet and gastrically infused with the Huganning Tablet solution of high-dosage (700 mg/kg/d), middle-dosage (350 mg/kg/d) and low-dosage(175 mg/kg/d), respectively. Four weeks later, all rats were sacrificed. Blood samples were collected to measure serum ALT, AST,TG,TC, LDL-C, GLU, SOD and MDA. Tissue samples were duly taken for histopathological examination and measurement of tissue TC, TG, LDL-C and MDA levels. Results There were lower levels of visceral adiposity ratio in Group B and Group C compared with Group Y( P <0. 05 ). There were low-er levels of serum AST, TC, GLU and liver tissue TC in Group A compared to Group Y(P<0.05). A significant increase was found in the serum SOD levels in Group A compared to Group Y( P < 0. 05). A significant reduction was observed in Group A in the hepatic steatosis, the grade of inflammation and the stage of fibrosis compared to Group Y and Group Z ( P < 0. 05). Conclusions Huganning Tablet seems to be effective in attenuating hepatic damage in the NASH model induced by a high-fat diet, which may become a potential drug for NASH treatment in the future.